<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267615</url>
  </required_header>
  <id_info>
    <org_study_id>VICIS</org_study_id>
    <nct_id>NCT03267615</nct_id>
  </id_info>
  <brief_title>VICIS - Vienna Cirrhosis Study</brief_title>
  <acronym>VICIS</acronym>
  <official_title>VICIS - Vienna Cirrhosis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced chronic liver diseases treated at the Vienna General Hospital of the
      Medical University of Vienna will be offered to participate in this prospective observational
      trial.

      Clinical parameters and laboratory parameters will be recorded for all patients and patients
      will undergo a regular follow-up schedule with clinical visits at the Vienna General
      Hospital.

      This study is linked to a biobank with serum/plasma, ascitic fluid, urine, GI tract mucosal
      biopsies, liver biopsies and stool collected from the study participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced chronic liver disease (ACLD) as evident by HVPG&gt;5mmHg or liver biopsy
      showing F3/F4 fibrosis or as suggested by liver stiffness measurement (LSM) &gt;15kPa can be
      included in the VICIS study. In fact most patients will be recruited on the day of HVPG
      measurement for screening for clinically significant portal hypertension (CSPH) or on the day
      of upper GI endoscopy for screening for the presence of varices. Next to the detailled
      characterization of patient characteristics by epidemiologic, clinical and laboratory
      parameters, the degree of portal hypertension will be assessed by HVPG, liver stiffness will
      be assessed by transient elastography, the presence of ascites, splenomegaly, portosystemic
      collaterals, PVT and liver lesions will be assessed by ultrasound. In addition, the included
      patients will be asked to participate in biobank sampling including serum/plasma, ascitic
      fluid, urine, GI tract mucosal biopsies, stool, liver biopsies and stool. All patients
      recruited in the VICIS study will be prospectively followed every 3 monhts (decompenated
      ACLD) or every 6 months (compensated ACLD) patients with clinical visits at the Cirrhosis
      Outpatient Clinic at the Vienna General Hospital. These assessments include the recording of
      decompensating events (such as ascites, hepatic encephalopathy, variceal bleeding), screening
      for PVT and HCC, and recording of medications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Transplant-free survival</measure>
    <time_frame>01/FEB/2017 - 31/DECEMBER/2027</time_frame>
    <description>Time from inclusion to death or liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decompensation-free survival</measure>
    <time_frame>01/FEB/2017 - 31/DECEMBER/2027</time_frame>
    <description>Time from inclusion to decompensation, death or liver transplantation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Ascites</condition>
  <condition>Variceal Hemorrhage</condition>
  <condition>Hepatic Encephalopathy</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, Serum, Urine, Stool, GI mucosa biopsies, ascitic fluid, liver tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with advanced chronic liver disease diagnosed and/or treated at the Medical
        University of Vienna will be screened for inclusion/exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years and &lt;100 years

          -  Diagnosis of advanced chronic liver disease (by liver stiffness &gt;15kPa, HVPG&gt;5mmHg or
             Histology F3/F4)

          -  Written informed consent

        Exclusion Criteria:

          -  Withdrawal of written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Reiberger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Reiberger, M.D.</last_name>
    <phone>+43140400</phone>
    <phone_ext>65890</phone_ext>
    <email>thomas.reiberger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mattias Mandorer, M.D.</last_name>
    <phone>+43140400</phone>
    <phone_ext>47410</phone_ext>
    <email>mattias.mandorfer@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Reiberger, M.D.</last_name>
      <phone>+43140400</phone>
      <phone_ext>47440</phone_ext>
      <email>thomas.reiberger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Weisgram</last_name>
      <phone>+43140400</phone>
      <phone_ext>47410</phone_ext>
      <email>alexandra.weisgram@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Mattias Mandorfer, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Schwabl, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Scheiner, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Reiberger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>May 30, 2020</last_update_submitted>
  <last_update_submitted_qc>May 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Thomas Reiberger</investigator_full_name>
    <investigator_title>Assoc.Prof.Priv.Doz.Dr.</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Portal Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

